In Brief: Biopharmaceutics
This article was originally published in The Tan Sheet
Executive Summary
Biopharmaceutics: Plans to purchase three feminine hygiene products -- Koromex spermicidal jellies, Vaginex medicated douches and itching relief products and Feminique douches -- from London International U.S. Holdings, the company announced Jan. 18. Biopharmaceutics expects to complete the agreement by Feb. 28; it would not disclose any dollar figures involved. The company expects the sales from the brands -- currently the company's only branded products -- to help the firm become profitable beginning in March. The products have been sold in the U.S. for over 10 years in chains including Walgreens, CVS and Eckerds. London International sold off the lines in order to concentrate on its "core" barrier protection products such as Sheik and Ramsey condoms. Biopharmaceutics is currently in negotiations for the purchase of a branded oral analgesics line...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning